Retina

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery

The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future treatments.

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).

Areas covered by the agreement would cover key Asian marketplaces, including Japan and China.

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings suggest that neurologic diseases impact ocular health.

Long-term benefits and vision preservation using an extended macular vision IOL

Telomir-1 shows promising results in restoring vision and retinal structure in age-related macular degeneration, marking a significant advancement in treatment.

The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.

The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

At ARVO 2025, in Salt Lake City, Utah, Emma Lessieur-Contreras, MD, PhD, talked about her poster on retina extracellular vesicles, and the role that they play on diabetic retinopathy.

Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease.

Lori Wright, JD, sat down to talk about a discussion at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.

Dilraj S. Grewal, MD, FASRS, provides an in-depth overview of the current state of research and treatment innovations.

Lysine, proline and arginine levels progressively increased from non-proliferative DR to proliferative DR stages

This partnership aims to address care gaps by identifying untreated and undertreated patients at scale.

Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections caused by povidone iodine.

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of 2 tissue patches in immediate succession while minimizing damage to the surrounding tissue.

ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

At ARVO 2025, in Salt Lake City, Utah, Steven Barnes, PhD, talked about his research on the OPA1 mutation in retinal ganglion cells' effect on the cell's electrical function.